Stock MDRX VERADIGM INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Veradigm Inc.

Equities

MDRX

US01988P1084

Advanced Medical Equipment & Technology

Market Closed - OTC Markets
Other stock markets
 03:59:56 2024-04-26 pm EDT 		5-day change 1st Jan Change
7.96 USD +0.13% Intraday chart for Veradigm Inc. +4.74% -24.12%
Apr. 03 Veradigm and Vim Announce Strategic Collaboration to Improve Payer-Provider Collaboration CI
Mar. 19 Deutsche Bank Downgrades Veradigm to Hold From Buy, Adjusts Price Target to $10 From $15 MT

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022 2023 2024
Capitalization 1 2,629 1,684 1,594 2,281 2,261 856.8 856.8 856.8
Enterprise Value (EV) 1 4,050 2,169 2,372 1,911 2,102 165 129.3 -11.91
P/E ratio -13.3 x 4.73 x -8.92 x 3.28 x 19 x -398 x 23.4 x 12.4 x
Yield - - - - - - - -
Capitalization / Revenue 1.43 x 0.79 x 0.9 x 1.39 x 1.5 x 1.39 x 1.37 x 1.32 x
EV / Revenue 2.2 x 1.02 x 1.34 x 1.17 x 1.4 x 0.27 x 0.21 x -0.02 x
EV / EBITDA 10.8 x 5.38 x 8.04 x 6.13 x 6.98 x 0.99 x 0.9 x -0.09 x
EV / FCF 43,023,435 x -28,266,975 x -28,171,749 x -9,027,301 x -13,648,454 x - - -
FCF Yield 0% -0% -0% -0% -0% - - -
Price to Book 2.35 x 1.09 x 1.24 x 1.21 x 1.52 x 0.85 x 0.79 x -
Nbr of stocks (in thousands) 180,681 174,714 162,366 157,982 122,572 107,640 107,640 107,640
Reference price 2 14.55 9.640 9.815 14.44 18.45 7.960 7.960 7.960
Announcement Date 2/15/18 2/21/19 3/2/20 2/25/21 2/24/22 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022 2023 2024
Net sales 1 1,841 2,129 1,774 1,640 1,503 616.9 624.6 649
EBITDA 1 373.6 403.4 295.1 311.9 301.1 166.8 143.3 138
EBIT 1 266.2 266.4 174.5 185.9 171.3 128.4 104 97.9
Operating Margin 14.46% 12.52% 9.84% 11.34% 11.4% 20.81% 16.64% 15.08%
Earnings before Tax (EBT) -209.6 13.1 -206.5 -149.3 161.8 - - -
Net income 1 -196.5 363.7 -182.2 700.4 134.4 -4.4 - -
Net margin -10.67% 17.09% -10.27% 42.72% 8.94% -0.71% - -
EPS 2 -1.090 2.040 -1.100 4.400 0.9700 -0.0200 0.3400 0.6400
Free Cash Flow 94.14 -76.73 -84.18 -211.7 -154 - - -
FCF margin 5.11% -3.6% -4.75% -12.91% -10.25% - - -
FCF Conversion (EBITDA) 25.2% - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/15/18 2/21/19 3/2/20 2/25/21 2/24/22 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 Q2 2020 Q3 2020 Q4 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4
Net sales 1 406.2 402.1 414.5 368.4 373.7 369.2 391.7 142.7 150.9 151.9 168.2 148.9 153.6 160.6 168.2
EBITDA 1 77.1 80.8 96.8 67.3 68.8 71.3 93.7 33.7 38.6 43.2 51.3 34 37 42.2 48.2
EBIT 1 45.3 48.5 65.8 37.9 33.4 35.1 64.9 23.9 29.1 33.7 41.8 24.1 26.9 31.9 37.7
Operating Margin 11.15% 12.06% 15.87% 10.29% 8.94% 9.51% 16.57% 16.75% 19.28% 22.19% 24.86% 16.19% 17.51% 19.86% 22.41%
Earnings before Tax (EBT) -0.7 1.5 -74.8 11.3 24.1 21.2 105.2 - - - - - - - -
Net income 1 -7.5 0.5 727.8 9.1 21.9 16.1 87.3 23.4 -64.1 14.6 22.2 - - - -
Net margin -1.85% 0.12% 175.59% 2.47% 5.86% 4.36% 22.29% 16.4% -42.48% 9.61% 13.2% - - - -
EPS 2 -0.0500 - 4.820 0.0600 0.1500 0.1200 0.6800 0.1700 -0.5600 0.1200 0.2100 0.0200 0.0400 0.1200 0.1700
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 7/30/20 10/29/20 2/25/21 4/29/21 8/5/21 11/4/21 2/24/22 5/5/22 8/4/22 11/3/22 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022 2023 2024
Net Debt 1 1,421 485 778 - - - - -
Net Cash position 1 - - - 370 160 692 728 869
Leverage (Debt/EBITDA) 3.805 x 1.201 x 2.636 x - - - - -
Free Cash Flow 94.1 -76.7 -84.2 -212 -154 - - -
ROE (net income / shareholders' equity) 9.6% 9.65% 7.9% 8.3% 12.7% 5.77% 6.93% -
ROA (Net income/ Total Assets) 2.8% 3.48% 3.51% - 7.28% 3.8% 5.23% -
Assets 1 -7,015 10,456 -5,195 - 1,845 -115.9 - -
Book Value Per Share 2 6.200 8.810 7.910 11.90 12.10 9.370 10.10 -
Cash Flow per Share 2 - 0.3800 0.2800 -0.6700 -0.5400 0.9100 1.040 -
Capex 46.4 31.3 16.6 17 78.6 - 39.6 -
Capex / Sales 2.52% 1.47% 0.94% 1.04% 5.23% - 6.34% -
Announcement Date 2/15/18 2/21/19 3/2/20 2/25/21 2/24/22 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
7.95 USD
Average target price
15 USD
Spread / Average Target
+88.68%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

1st Jan change Capi.
VERADIGM INC. Stock Veradigm Inc.
-24.12% 856M
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+4.36% 32.18B
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+14.14% 7.33B
SECTRA AB Stock Sectra AB
+22.93% 3.83B
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-16.29% 3.23B
OMNICELL, INC. Stock Omnicell, Inc.
-25.96% 1.25B
LUNIT INC. Stock Lunit Inc.
-36.14% 1.12B
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
-0.13% 912M
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-35.42% 859M
SURGICAL SCIENCE SWEDEN AB Stock Surgical Science Sweden AB
-18.47% 661M
Medical Software & Technology Services
  1. Stock Market
  2. Equities
  3. MDRX Stock
  4. Financials Veradigm Inc.